Citadel Advisors’s Tevogen Bio Holdings TVGN Stock Holding History

Citadel Advisors’s Portfolio TVGN Stock Details TVGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-345	Closed	-$5.71K	–	14444
2025 Q4	$5.71K	Buy	+345	New	+$8.97K	﹤0.01%	12461
2024 Q3	–	Sell	-968	Closed	-$35K	–	15409
2024 Q2	$35K	Buy	+968	New	+$63.1K	﹤0.01%	12121
2023 Q4	–	Sell	-18,663	Closed	-$10.1M	–	15406
2023 Q3	$10.1M	Buy	+18,663	New	+$10.1M	﹤0.01%	2683
2022 Q2	–	Sell	-5,001	Closed	-$2.5M	–	14286
2022 Q1	$2.5M	Buy	+5,001	New	+$2.49M	﹤0.01%	5599

Other funds holding TVGN

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Citadel Advisors's TVGN Position: Q1 2026 in Review

Citadel Advisors sold out of Tevogen Bio Holdings (TVGN) in Q1 2026, closing a stake of 345 shares — an estimated $5.71K sold.

Citadel Advisors first reported a position in TVGN in Q1 2022 and held it in 4 quarters. The position peaked at $10.1M in Q3 2023. 30 funds tracked by Wall St. Rank hold TVGN as of Q1 2026.

Citadel Advisors reported no remaining Tevogen Bio Holdings position as of Q1 2026 after selling out during the quarter.
Citadel Advisors sold 345 Tevogen Bio Holdings shares in Q1 2026, an estimated $5.71K.
Citadel Advisors first reported a position in Tevogen Bio Holdings in Q1 2022 and held it in 4 quarters.
Citadel Advisors's Tevogen Bio Holdings position peaked at $10.1M in Q3 2023.
30 funds tracked by Wall St. Rank held Tevogen Bio Holdings as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.